Progress in drug therapy of Wilson's disease
10.3760/cma.j.cn501113-20240714-00324
- VernacularTitle:威尔逊氏病的药物治疗进展
- Author:
Wei ZHANG
1
;
Xinyan ZHAO
;
Jian HUANG
;
Xiaojuan OU
;
Jidong JIA
Author Information
1. 首都医科大学附属北京友谊医院肝病中心，北京 100050
- Keywords:
Wilson disease;
Drug;
Therapeutic;
Chelating agent;
New drug
- From:
Chinese Journal of Hepatology
2024;32(9):783-786
- CountryChina
- Language:Chinese
-
Abstract:
Wilson's disease, also known as hepatolenticular degeneration, is an inherited disorder of copper metabolism caused by homozygous or compound heterozygous variants in the ATP7B gene, which is mainly clinically manifested as liver disease and/or neurological/psychological disorders, and Kayser-Fleischer ring in the peripheral cornea. Patients with Wilson's disease are currently treated with lifelong use of chelating agents that promote copper ion excretion and/or zinc agents that reduce copper absorption, but there is still an unmet clinical need because some patients who receive treatment have poor efficacy, disease progression, or serious adverse drug reactions. In recent years, new therapeutic drugs have been developed rapidly. This article will summarize the advances in drug treatment of Wilson's disease, shedding new light on the treatment of Wilson's disease.
